Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for October 5, 2021

10/5/2021

 
Regulatory Update
 
The FDA approved atogepant (Qulipta, AbbVie), on 9/29/2021, for the prevention of episodic migraine. The most common adverse events with atogepant are constipation, nausea and fatigue.
 
The FDA approved maralixibat (Livmarli, Mirum Pharmaceuticals), on 9/29/2021, for the treatment of cholestatic pruritus in patients with Alagille syndrome. Maralixibat will only be available through the Mirum Access Plus (MAP) program, a single-source specialty pharmacy owned by Mirum Pharmaceuticals.
 
Biogen and Eisai initiated a rolling BLA submission for lecanemab for the treatment of early Alzheimer's disease.
 
The FDA accepted the NDA for 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer, which suggested a PDUFA date of 3/29/2022.
 
Announced Research Updates
 
Pfizer is evaluating fordadistrogene movaparvovec as treatment for Duchenne muscular dystrophy in a 99 patient, Phase III trial. Due to three cases of muscle weakness and heart inflammation in two of the cases, Pfizer is amending the Phase III trial protocol to exclude patients with mutations affecting exons 9 through 13, or a deletion that affects both exon 29 and exon 30.
 
BE BRIGHT is a long-term extension of the BE READY, BE VIVID and BE SURE trials. UCB announced that in the 1,355 patient, open-label, Phase III, BE BRIGHT trial, treatment with bimekizumab resulted in PASI 90 being achieved by 91% of BE SURE patients who had originally received bimekizumab and 72.3% achieving PASI 100 at 104 weeks. Similar response rates were achieved by patients switched from adalimumab in BE SURE to bimekizumab in BE BRIGHT. 69.9% of BE VIVID patients switched from ustekinumab to bimekizumab achieved PASI 100 at week 100.
 
Lilly announced that in the 52-week, 243 patient, SURPASS-3 CGM sub-study, 72.6% of patients treated with tirzepatide maintained blood glucose in the target range of 71-140 mg/dL compared to 48% of patients treated with insulin degludec. Tirzepatide patients also spent less time in the hypoglycemia range of 70 mg/dL or less (0.6% vs 1.0%).
 
Lilly announced that in a 104-week, Phase II trial, 186 patients with moderate-to-severe active ulcerative colitis (UC) received mirikizumab for 12-weeks. 93 patients responded and were randomized to mirikizumab every 4 weeks or every 12 weeks. After 52-weeks, 92.5% (86/93) continued taking mirikizumab and 82.1% achieved rectal bleeding remission and 84.6% achieved stool frequency remission. After two years, 83.9% remained on mirikizumab with 85.9% maintaining rectal bleeding remission and 84.6% maintaining stool frequency remission.
 
Published Research Updates
 
In the 69 patient, Phase IlI, FOCUS4-C trial, treatment with adavosertib improved progression free survival compared to active monitoring (3.61 vs 1.87 months) in metastatic colorectal cancer patients with TP53 and RAS mutations.
 
A 143 patient, Phase II trial was stopped early when an interim analysis of the first 123 patients found no improvement in overall survival when adding veliparib to mFOLFIRI  compared to FOLFIRI alone (5.4 vs 6.5 months) in patients with metastatic pancreatic cancer.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.